I. Introduction
Familial hypercholesterolemia (FH) is a common inherited disorder of lipid metabolism, characterized by very high LDL cholesterol levels and early-onset atherosclerotic cardiovascular disease (ASCVD).
- Inheritance: usually autosomal dominant.
- Frequency: ~1 in 250 for heterozygous FH (HeFH); ~1 in 300,000–1,000,000 for homozygous FH (HoFH).
- Pathogenesis: impaired clearance of LDL particles from plasma due to mutations affecting the LDL receptor pathway.
II. Molecular Basis
FH is caused by mutations in genes regulating LDL uptake:
- LDLR gene (most common) → defective or absent LDL receptors → reduced clearance of LDL cholesterol.
- APOB gene → defective apolipoprotein B-100 (ligand for LDLR).
- PCSK9 gene → gain-of-function mutations → increased degradation of LDL receptors.
Result: elevated plasma LDL cholesterol, accelerated atherosclerosis.
III. Pathogenesis
- Mutations impair binding or recycling of LDL receptors.
- LDL particles remain in circulation → plasma LDL cholesterol ↑↑.
- Excess LDL infiltrates arterial intima → foam cell formation, atherosclerotic plaques.
- Cholesterol deposition also occurs in skin and tendons → xanthomas.
- Severe premature atherosclerosis → early myocardial infarction and stroke.